ZYBERNO
Stock Report
Updated Sep 1, 2026

WEREWOLF THERAPEUTICS, INC. (HOWL)

Healthcare • NASDAQ

$0.94

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
WEREWOLF THERAPEUTICS, INC. (HOWL) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-167.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.15x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,081.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

WEREWOLF THERAPEUTICS, INC. (HOWL) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, HOWL generated -$60.29M in Owner Earnings. Reinvestment rate: 7.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.94
Market Cap:$45.73M

Valuation Multiples (2)

P/B Ratio:2.81x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$23.74M

Price Action & Momentum (3)

Momentum Percentile:4 / 100
% of 52-Week High:39.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-59.9%
Reinvestment Rate:7.0%
Fundamental Growth Rate (g):-75.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$180.38
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-83.4%
Latest Earnings Filed:2026-07-31
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.91x
Quick Ratio:2.91x
Cash Ratio:2.80x

Leverage Analysis (3)

Debt To Equity Ttm:0.15x
Debt-to-Equity Ratio:0.15x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-13.33x
Times Interest Earned:-13.33

Capital Structure (4)

Working Capital:15,029,000.00
Cash And Cash Equivalents:21,987,000.00
Long Term Debt:$0.00
Net Debt:-$21.99M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$31.26M

Bottom Line Performance (3)

-$34.61M
Income Before Tax:$0.00
Ebitda Ttm:-29,651,000.00

Operating Expenses (5)

Operating Expenses:52,257,000.00
R And D Expense:32,910,000.00
Sga Expense:19,347,000.00
Income Tax Expense:$0.00
Interest Expense:4,553,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$24.16M
Current Assets:$22.89M
Ppe Net:1,263,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:7,863,000.00
Current Liabilities:7,863,000.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$16.29M
Retained Earnings:-$485.27M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:5,924,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:419,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$51.94M-$60.29M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:0.00

Financing Activities (3)

Financing Cash Flow:$2.37M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:5,939,000.00
Long Term Debt Issuance:$30.00M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,606,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.72
-$0.73
Earnings Per Share Ttm:-$0.71

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.24

Book Value & Capital (2)

Book Value Per Share:$0.34
Cash Per Share:0.45

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$60.29M

Damodaran Growth Analysis (2)

Reinvestment Rate:7.0%
Fundamental Growth Rate (g):-75.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-41.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:HOWL
Company Name:WEREWOLF THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:48.60M
Shares Outstanding Basic:48.60M
Shares Outstanding Diluted:48.60M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 13:07:13 UTC
Data Timestamp:2026-08-21T07:08:09.674358
Scroll to Top